A Phase II, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients with Stage IIIB or IV Non-Small Cell Lung Cancer
Conditions
Non Small Cell Lung Cancer
Trial Phase
Trial Purpose and Description
Trial Purpose
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Eligibility Criteria
- Sponsor:
- Infinity Pharmaceuticals
- Dates:
- June 2011
- Last Updated:
- Study HIC#:
- 1104008281
Clinicaltrials.gov ID: Yale8017803
For more information about this trial, contact:
Investigator
Scott Gettinger, MD
Principal Investigator
